NASDAQ$ADPT
Adaptive Biotechnologies Corporation · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Adaptive Biotechnologies reported a decrease in revenue and net loss for Q3 2023, while highlighting progress in MRD test volume growth and Immune Medicine target discovery.
Adaptive Biotechnologies reported a 21% decrease in revenue compared to the third quarter of the prior year, driven by reductions in GNE amortization and MRD/IM pharma services. The company is undergoing a strategic review to maximize the value of its MRD and Immune Medicine businesses. clonoSEQ test volume grew 56% year-over-year.
- Revenue for Q3 2023 was $37.9 million, a 21% decrease from Q3 2022.
- clonoSEQ test volume in Q3 2023 grew 56% to 15,072 tests delivered versus the third quarter of prior year.
- Immune Medicine achieved a key milestone with the discovery of a novel target in multiple sclerosis.
- Operating expenses, excluding cost of revenue, for Q3 2023 decreased 11% versus the same period last year.
Headline financials
Revenue & EPS history
Adaptive Biotechnologies · Revenue · Quarterly
$37.9M
Revenue by segment
Adaptive Biotechnologies · $38M total across 2 segments · Q3 2023
- MRD$24.7M+23.5%65.0%
- Immune Medicine$13.3M-52.3%35.0%
Forward guidance
Adaptive Biotechnologies is updating full year 2023 revenue guidance to exclude revenue from the Immune Medicine business.
Tailwinds
- MRD business full year 2023 revenue to be in the range of $100 million to $105 million.
- Total company operating expenses, including cost of revenue, for full year 2023 to be around $375 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2023
+1.3%
Avg return
Earnings day
+0.0%
Avg return
5 days after
-0.9%
Avg return
30 days after
48%
13 / 27 earnings
Positive
+33.2%
Q1 2025
Best reaction
-22.2%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +1.2% | -1.9% | +22.6% | |
| Q4 2025 | -4.3% | -5.2% | -9.8% | |
| Q3 2025 | -4.8% | -6.8% | -5.2% | |
| Q1 2025 | +33.2% | +19.7% | +29.3% | |
| Q4 2024 | -3.2% | +6.8% | -6.7% | |
| Q3 2024 | +1.2% | +3.1% | +9.0% | |
| Q2 2024 | -5.5% | +1.3% | +3.3% | |
| Q1 2024 | -1.2% | +8.7% | +21.1% | |
| Q4 2023 | +9.4% | +6.4% | -10.5% | |
| Q3 2023 | -22.2% | -9.3% | +4.4% | |
| Q2 2023 | -15.5% | -18.8% | -17.5% | |
| Q1 2023 | -8.3% | -5.8% | +6.4% | |
| Q4 2022 | +15.4% | +9.3% | -3.3% | |
| Q3 2022 | +13.2% | -0.9% | +14.1% | |
| Q2 2022 | +19.3% | +22.8% | -8.4% | |
| Q1 2022 | -1.1% | -19.2% | -22.5% | |
| Q4 2021 | +5.3% | -8.0% | -15.3% | |
| Q3 2021 | +6.7% | +5.7% | -26.6% | |
| Q2 2021 | +4.8% | -2.4% | +9.8% | |
| Q1 2021 | +0.9% | -11.2% | -1.0% | |
| Q4 2020 | -2.6% | +2.0% | -32.8% | |
| Q3 2020 | +8.0% | +2.1% | +14.9% | |
| Q2 2020 | -3.8% | +2.8% | +0.2% | |
| Q1 2020 | -6.7% | -0.2% | +9.9% | |
| Q4 2019 | -5.6% | -10.7% | -15.4% | |
| Q3 2019 | -3.7% | +0.7% | +11.8% | |
| Q2 2019 | +3.5% | +9.7% | -5.4% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro